• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …

Myocardial interstitial fibrosis contributes to left ventricular dysfunction leading to the
development of heart failure. Basic research has provided abundant evidence for the …

Background Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often
experience a high burden of symptoms; however, there are no proven pharmacological …

Abstract Background: The HCMR (Hypertrophic Cardiomyopathy Registry) is a National
Heart, Lung, and Blood Institute–funded, prospective registry of 2,755 patients with …

Left ventricular (LV) hypertrophy consists in an increased LV wall thickness. LV hypertrophy
can be either secondary, in response to pressure or volume overload, or primary, ie not …

Background: Left ventricular (LV) scar on late gadolinium enhancement (LGE) cardiac
magnetic resonance has been correlated with life-threatening arrhythmic events in patients …

Noninvasive contemporary imaging with echocardiography and cardiovascular magnetic
resonance (CMR) provide comprehensive characterization of the hypertrophic …